PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12601049-0	2003	Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression.	Budesonide	69-79	vascular endothelial growth factor A	Homo sapiens	120-124	
12601049-1	2003	PURPOSE: The purpose of this study was to determine whether budesonide inhibits expression of vascular endothelial growth factor (VEGF) in a retinal pigment epithelial cell line (ARPE-19) and to determine whether subconjunctivally administered budesonide nano- and microparticles sustain retinal drug levels.	Budesonide	60-70	vascular endothelial growth factor A	Homo sapiens	94-128	
12601049-1	2003	PURPOSE: The purpose of this study was to determine whether budesonide inhibits expression of vascular endothelial growth factor (VEGF) in a retinal pigment epithelial cell line (ARPE-19) and to determine whether subconjunctivally administered budesonide nano- and microparticles sustain retinal drug levels.	Budesonide	60-70	vascular endothelial growth factor A	Homo sapiens	130-134	
12601049-6	2003	RESULTS: At concentrations devoid of cytotoxicity, budesonide inhibited VEGF secretion as well as mRNA expression in ARPE-19 cells in a dose-dependent manner.	Budesonide	51-61	vascular endothelial growth factor A	Homo sapiens	72-76	
12601049-7	2003	RU486 treatment prevented budesonide-mediated inhibition of VEGF secretion and VEGF mRNA expression.	Budesonide	26-36	vascular endothelial growth factor A	Homo sapiens	60-64	
12601049-7	2003	RU486 treatment prevented budesonide-mediated inhibition of VEGF secretion and VEGF mRNA expression.	Budesonide	26-36	vascular endothelial growth factor A	Homo sapiens	79-83	
12601049-10	2003	CONCLUSIONS: Budesonide is capable of inhibiting VEGF expression through glucocorticoid receptor activity.	Budesonide	13-23	vascular endothelial growth factor A	Homo sapiens	49-53